These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 34734816)
21. Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting. Nordberg Backelin C; Fu M; Ljungman C ESC Heart Fail; 2020 Jun; 7(3):1049-1055. PubMed ID: 32030899 [TBL] [Abstract][Full Text] [Related]
22. LCZ696 ameliorates doxorubicin-induced cardiomyocyte toxicity in rats. Miyoshi T; Nakamura K; Amioka N; Hatipoglu OF; Yonezawa T; Saito Y; Yoshida M; Akagi S; Ito H Sci Rep; 2022 Mar; 12(1):4930. PubMed ID: 35322164 [TBL] [Abstract][Full Text] [Related]
23. Assessing the cardioprotective effect of necrosulfonamide in doxorubicin-induced cardiotoxicity in mice. Abbas SF; Abdulkadim H; Hadi NR J Med Life; 2023 Oct; 16(10):1468-1473. PubMed ID: 38313169 [TBL] [Abstract][Full Text] [Related]
24. Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats. Alqahtani F; Mohany M; Alasmari AF; Alanazi AZ; Belali OM; Ahmed MM; Al-Rejaie SS Int J Med Sci; 2020; 17(18):3098-3106. PubMed ID: 33173431 [No Abstract] [Full Text] [Related]
25. Sacubitril/valsartan attenuates myocardial ischemia/reperfusion injury via inhibition of the GSK3β/NF-κB pathway in cardiomyocytes. Xiao F; Wang L; Liu M; Chen M; He H; Jia Z; Zhang L; Yang Y; Hu Q; Hong M; Zhang H Arch Biochem Biophys; 2022 Nov; 730():109415. PubMed ID: 36179911 [TBL] [Abstract][Full Text] [Related]
27. Benefits of early administration of Sacubitril/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Zhang Y; Wu Y; Zhang K; Ke Z; Hu P; Jin D Coron Artery Dis; 2021 Aug; 32(5):427-431. PubMed ID: 32868662 [TBL] [Abstract][Full Text] [Related]
28. β-Caryophyllene, a natural bicyclic sesquiterpene attenuates doxorubicin-induced chronic cardiotoxicity via activation of myocardial cannabinoid type-2 (CB Meeran MFN; Al Taee H; Azimullah S; Tariq S; Adeghate E; Ojha S Chem Biol Interact; 2019 May; 304():158-167. PubMed ID: 30836069 [TBL] [Abstract][Full Text] [Related]
29. Protective effects of olmesartan and l-carnitine on doxorubicin-induced cardiotoxicity in rats. Aziz MM; Abd El Fattah MA; Ahmed KA; Sayed HM Can J Physiol Pharmacol; 2020 Apr; 98(4):183-193. PubMed ID: 31665614 [TBL] [Abstract][Full Text] [Related]
30. Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits. Yu C; Li D; Li Z; Yu D; Zhai G Acta Pharm; 2021 Sep; 71(3):473-484. PubMed ID: 36654091 [TBL] [Abstract][Full Text] [Related]
31. Carvedilol (CAR) combined with carnosic acid (CAA) attenuates doxorubicin-induced cardiotoxicity by suppressing excessive oxidative stress, inflammation, apoptosis and autophagy. Zhang QL; Yang JJ; Zhang HS Biomed Pharmacother; 2019 Jan; 109():71-83. PubMed ID: 30396094 [TBL] [Abstract][Full Text] [Related]
33. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension. Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157 [TBL] [Abstract][Full Text] [Related]
34. All-trans-retinoic acid ameliorates doxorubicin-induced cardiotoxicity: in vivo potential involvement of oxidative stress, inflammation, and apoptosis via caspase-3 and p53 down-expression. Khafaga AF; El-Sayed YS Naunyn Schmiedebergs Arch Pharmacol; 2018 Jan; 391(1):59-70. PubMed ID: 29085977 [TBL] [Abstract][Full Text] [Related]
35. Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide. Liu C; Long Q; Yang H; Yang H; Tang Y; Liu B; Zhou Z; Yuan J Biomed Pharmacother; 2024 May; 174():116535. PubMed ID: 38581923 [TBL] [Abstract][Full Text] [Related]
36. Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Mantawy EM; El-Bakly WM; Esmat A; Badr AM; El-Demerdash E Eur J Pharmacol; 2014 Apr; 728():107-18. PubMed ID: 24509133 [TBL] [Abstract][Full Text] [Related]
37. Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Abdel-Daim MM; Kilany OE; Khalifa HA; Ahmed AAM Cancer Chemother Pharmacol; 2017 Oct; 80(4):745-753. PubMed ID: 28785995 [TBL] [Abstract][Full Text] [Related]
38. Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline-induced takotsubo-like syndrome. Ali A; Redfors B; Alkhoury J; Oras J; Henricsson M; Boren J; Björnson E; Espinosa A; Levin M; Gan LM; Omerovic E ESC Heart Fail; 2021 Oct; 8(5):4130-4138. PubMed ID: 34463049 [TBL] [Abstract][Full Text] [Related]
39. Sacubitril/Valsartan Improves Left Ventricular Function in Chronic Pressure Overload Independent of Intact Cyclic Guanosine Monophosphate-dependent Protein Kinase I Alpha Signaling. Tam K; Richards DA; Aronovitz MJ; Martin GL; Pande S; Jaffe IZ; Blanton RM J Card Fail; 2020 Sep; 26(9):769-775. PubMed ID: 32464187 [TBL] [Abstract][Full Text] [Related]
40. Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF. Myhre PL; Prescott MF; Murphy SP; Fang JC; Mitchell GF; Ward JH; Claggett B; Desai AS; Solomon SD; Januzzi JL JACC Heart Fail; 2022 Feb; 10(2):119-128. PubMed ID: 35115085 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]